Teva only has right to the Bio-t-gel in the US, the right to the rest of the world still belong to Biosante. So yes approval will mean something to BPAX. In all likelihood Teva would negotiate a new licencing agreement which would be more profitable for BPAX for the remaining rights. Teva has around 47,000 employees in over 60 countries. Feb 14th PDUFA is about BPAX getting the foot in the door.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.